Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Rizza

Showing results (11-20 of 314) with videos related to

Pageof 32
Sort By:
Diabetes|January 1, 1991
Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patientsP C Butler, R A Rizza
Endocrinology and Metabolism Clinics of North America|March 1, 1989
Regulation of carbohydrate metabolism and response to hypoglycemiaP C Butler, R A Rizza
Drugs of Today (Barcelona, Spain : 1998)|November 10, 2017
Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in childrenS A Rizza, V Nehra, Z Temesgen
Drugs of Today (Barcelona, Spain : 1998)|July 2, 2014
Sofosbuvir for the treatment of chronic hepatitis C virus infectionZ Temesgen, R Talwani, S A Rizza
Diabetes|May 22, 2016
Accurate Measurement of Postprandial Glucose Turnover: Why Is It Difficult and How Can It Be Done (Relatively) Simply?Robert A Rizza, Gianna Toffolo, Claudio Cobelli
Drugs of Today (Barcelona, Spain : 1998)|May 28, 2019
Dolutegravir plus lamivudine dual therapy - a new option for initial antiretroviral therapyM Fida, S A Rizza, Z Temesgen
Current Opinion in Clinical Nutrition and Metabolic Care|June 12, 2004
The gastrointestinal tract and glucose toleranceAdrian Vella, Michael Camilleri, Robert A Rizza
Drugs of Today (Barcelona, Spain : 1998)|August 10, 2018
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection in adultsV Nehra, S A Rizza, Z Temesgen
Drugs of Today (Barcelona, Spain : 1998)|February 14, 2014
Dolutegravir, an HIV integrase inhibitor for the treatment of HIV infectionZ Temesgen, R Talwani, S A Rizza
Drugs of Today (Barcelona, Spain : 1998)|April 28, 2017
Sofosbuvir/velpatasvir fixed-dose combination for the treatment of chronic hepatitis C virus infectionV Nehra, S A Rizza, Z Temesgen
Pageof 32

Showing results (11-20 of 314) with videos related to

Sort By:
Pageof 32
Diabetes|January 1, 1991
Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patientsP C Butler, R A Rizza
Endocrinology and Metabolism Clinics of North America|March 1, 1989
Regulation of carbohydrate metabolism and response to hypoglycemiaP C Butler, R A Rizza
Drugs of Today (Barcelona, Spain : 1998)|November 10, 2017
Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in childrenS A Rizza, V Nehra, Z Temesgen
Drugs of Today (Barcelona, Spain : 1998)|July 2, 2014
Sofosbuvir for the treatment of chronic hepatitis C virus infectionZ Temesgen, R Talwani, S A Rizza
Diabetes|May 22, 2016
Accurate Measurement of Postprandial Glucose Turnover: Why Is It Difficult and How Can It Be Done (Relatively) Simply?Robert A Rizza, Gianna Toffolo, Claudio Cobelli
Drugs of Today (Barcelona, Spain : 1998)|May 28, 2019
Dolutegravir plus lamivudine dual therapy - a new option for initial antiretroviral therapyM Fida, S A Rizza, Z Temesgen
Current Opinion in Clinical Nutrition and Metabolic Care|June 12, 2004
The gastrointestinal tract and glucose toleranceAdrian Vella, Michael Camilleri, Robert A Rizza
Drugs of Today (Barcelona, Spain : 1998)|August 10, 2018
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection in adultsV Nehra, S A Rizza, Z Temesgen
Drugs of Today (Barcelona, Spain : 1998)|February 14, 2014
Dolutegravir, an HIV integrase inhibitor for the treatment of HIV infectionZ Temesgen, R Talwani, S A Rizza
Drugs of Today (Barcelona, Spain : 1998)|April 28, 2017
Sofosbuvir/velpatasvir fixed-dose combination for the treatment of chronic hepatitis C virus infectionV Nehra, S A Rizza, Z Temesgen
Pageof 32